ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

tremelimumab

Also written as “Tremelimumab”, “CP-675,206” and “MEDI4736 + tremelimumab”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Carcinoma, Hepatocellular · Melanoma · Small Cell Lung Carcinoma · Squamous Cell Carcinoma of Head and Neck, led by 2 companies.

Drug pageTremelimumab: every studyAll 221 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Nov 18, 200547 company-led studies, 18 open or runningNext primary completion: Nov 30, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZenecaits history only4618 open or runningphase 3since Nov 18, 2005Jul 1, 2004Nov 30, 2026phase 2 · NCT07081633
Pfizer10 open or runningphase 2since Jun 19, 2007Jun 19, 2007none ahead

Also a collaborator on its studies: PRA Health Sciences and Quintiles.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Pfizer only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 19, 2007First study: phase 2 study in Acquired Immunodeficiency SyndromeFirst studyNCT00488995

TargetBeta

CTLA4 →read by rule
“A human IgG2 monoclonal antibody directed against the T-cell receptor protein cytotoxic T-lymphocyte-associated protein 4 (CTLA4)”NCIt, by rule
“Cytotoxic T-lymphocyte protein 4 inhibitor”ChEMBL 37, by rule

Other programs on CTLA4

ProgramCompanyFurthest phaseStudies
cadonilimabruleAkesophase 345
Iparomlimab/TuvonralimabruleQilu Pharmaceuticalphase 322
volrustomigAstraZenecaphase 319
Anti-CTLA-4 Monoclonal Antibody SHR-8068ruleJiangsu HengRui Medicinephase 316
erfonrilimabruleAlphamab Oncologyphase 314
Anti-CTLA-4 Monoclonal Antibody IBI310ruleInnovent Biologicsphase 311
gotistobartruleoncoc4-incphase 35
zalifrelimabruleAgenusphase 26
porustobartruleharbour-biomed-guangzhou-co-ltdphase 25
lorigerlimabruleMacroGenicsphase 24
Anti-PD-1/Anti-CTLA-4/Anti-VEGF Trispecific Antibody HC010rulehc-biopharma-incphase 22
GB268ruleeddingpharm-zhuhai-co-ltdphase 22

Studies

The one study Pfizer leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT00488995Acquired Immunodeficiency Syndrome2Withdrawn0

How it is read

Names in the registry

  • “Tremelimumab”, 22 entries
  • “CP-675,206”, 12 entries
  • “tremelimumab”, 7 entries
  • “MEDI4736 + tremelimumab”, 3 entries
  • “MEDI4736 + Tremelimumab”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.